By Chris Wack

IDEAYA Biosciences said Wednesday that the U.S. Food and Drug Administration has granted fast-track designation to its development program investigating IDE161 for the treatment of adult patients having advanced or metastatic hormone receptor positive, Her2- breast cancer with germline or somatic BRCA 1/2 mutations.

IDE161 is the company's potent and selective inhibitor of poly glycohydrolase in both BRCA1/2-mutant breast and ovarian cancers.

Fast track is a U.S. FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

IDEAYA's Phase 1 first-in-human clinical trial is evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties and preliminary efficacy of IDE161 in patients having solid tumors with homologous recombination deficiency.

IDEAYA is targeting program updates for IDE161 in the fourth quarter of 2023. The company owns or controls all commercial rights in IDE161, subject to certain economic obligations under its exclusive, worldwide license with Cancer Research UK and University of Manchester.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

September 27, 2023 06:28 ET (10:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
IDEAYA Biosciences (NASDAQ:IDYA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos IDEAYA Biosciences.
IDEAYA Biosciences (NASDAQ:IDYA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos IDEAYA Biosciences.